Abbvie’s New Blockbuster Drug For Rheumatoid Arthritis

AbbVie has recently made headlines owing to various different ventures that it has been making in the pharmaceutical community. Whether it is introducing new drugs or antibiotics to the medical industry, or investing in collaborations with other pharmaceutical companies, AbbVie has definitely established itself as a pioneer in several medical fields. In recent news, AbbVie has received official approval by the FDA for their brand new drug, Rinvoq. This drug mainly aims to treat adults with early/late onset, moderate to severe forms of Rheumatoid Arthritis (RA). The exact details and recommended dosage etc. can be found in the sections below. 

What is Rinvoq? 

For starters, Rinvoq is a drug designed to combat Rheumatoid Arthritis. It has been optimized for patients who have experienced or reported inadequate responses from other drugs such as Methotrexate based ones. This includes the pool of patients who are intolerant to the aforementioned drugs, and so Rinvoq has appeared on the scene. Distribution of Rinvoq is expected to start in August this year to pharmaceutical companies all over the United States. 

Rinvoq has been in the works for quite a while. It is part of the FDA’s SELECT program campaign that has recently undergone three different phases of approval for the treatment of RA. Clinical trials have been held by housing over forty thousand under analysis on a nationwide scale. These trials and studies have taken into account patient histories with particular attention to Methotrexate based drugs to the treatment of RA specifically. 

Image via AbbVie

How does it work? 

While Rinvoq is a relatively new venture as compared to its predecessor Humira, AbbVie hopes that it will leave a mark as well. Now, patients who have undergone trials with Rinvoq have been reported to be in clinical remission ever since the start of treatment. Although some of these patients were thought to be under the placebo effect, most did accurately report having achieved remission around the twelve-week mark. This clinical remission supposedly lasts till the twenty-four or twenty-six-week mark. Some side effects of Rinvoq, however, may be a source of alarm because they entail a wide range of lung tract infections that may even prove fatal in the long run. 

Future Prospects for Rinvoq

Aside from the work that needs to be done to improve upon potential side effects and setbacks from the Rinvoq treatment, AbbVie is also looking forward to releasing another brand new drug into the market not too far into this year. With approvals for such drugs by the FDA, the pharmaceutical industry can definitely hope for more improvements and new treatments in order to help more patients that are ailing with disorders much like RA itself. 


With cases of Rheumatoid Arthritis riddling a large chunk of the adult population in the United States, a drug such as Rinvoq has been long overdue, and AbbVie has indeed taken the time to perfect it and present it to the public such that they reap the benefits in the long term.

Will AbbVie will win the market share for Rheumatoid Arthritis? Comment your thoughts!

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.